Philadelphia chromosome-positive acute myeloid leukemia (Ph + AML) treated with imatinib mesylate (IM): A report with IM plasma concentration and bcr-abl

详细信息    查看全文

• 作者：Toshinori Kondo ; Taizo Tasaka ; Fuminori Sano ; Kimiko Matsuda ; Yasutaka Kubo ; Yoshiko Matsuhashi ; Hidekazu Nakanishi ; Yoshito Sadahira ; Hideho Wada ; Takashi Sugihara ; Kaoru Tohyama
• 关键词：Pharmacokinetics ; Imatinib mesylate ; Acute myeloid leukemia
• 刊名：Leukemia Research
• 出版年：2009
• 出版时间：September 2009
• 年：2009
• 卷：33
• 期：9
• 页码：e137-e138
• 全文大小：159 K

文摘

We studied the efficacy and pharmacokinetics of imatinib mesylate (IM) and bcr-abl expression in a Philadelphia chromosome-positive acute myeloid leukemia (Ph + AML) patient, a rare disease with a poor prognosis. Although sufficient IM trough concentrations were maintained, bcr-abl transcripts revealed only one-log reduction with IM monotherapy, suggesting a resistance against IM, and this patient required additional chemotherapy. Despite the resistance against IM at induction therapy, the patient has been in complete molecular response for more than 6 months with IM maintenance monotherapy. Our experience suggests that IM might have a positive role in consolidation and/or maintenance therapy in remission Ph + AML patients.